FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      
1. Name and Address of Reporting Person * SOLAND DANIEL B 2. Issuer Name and Ticker or Trading Symbol ACADIA PHARMACEUTICALS INC [ ACAD ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)__X__ Director                    _____ 10% Owner
_____ Officer (give title below)    _____ Other (specify below)
(Last)         (First)         (Middle)
C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400
3. Date of Earliest Transaction (MM/DD/YYYY)
6/22/2021
(Street)
SAN DIEGO, CA 92130
(City)       (State)       (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)
 
6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Director Stock Options (Right to Buy)  $24.88  6/22/2021    A     11637       (1) 6/21/2031  Common Stock  11637  $0.00  11637  D   
Restricted Stock Units   (2) 6/22/2021    A     6391       (3)  (3) Common Stock  6391  $0.00  6391  D   

Explanation of Responses:
(1)  The shares subject to the option shall vest quarterly over one year following the date of grant, with the final tranche vesting upon the earlier of one year following the date of grant or the next annual meeting date.
(2)  Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock.
(3)  The restricted stock units shall vest in full upon the earlier of one year following the date of grant or the next annual meeting date.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
SOLAND DANIEL B
C/O ACADIA PHARMACEUTICALS INC.
12830 EL CAMINO REAL, SUITE 400
SAN DIEGO, CA 92130
X



Signatures
/s/ Austin D. Kim, Attorney-in-Fact 6/23/2021
**Signature of Reporting Person Date
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Nov 2021 to Dec 2021 Click Here for more Acadia Pharmaceuticals Charts.
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Dec 2020 to Dec 2021 Click Here for more Acadia Pharmaceuticals Charts.